Author name: amit-oss

In the digital age, where information flows freely across the globe, the power dynamics of who controls that flow have never been more crucial. YouTube censorship is increasingly becoming a hotbed of controversy, especially concerning alternative cancer treatments like vitamin B17 (amygdalin). Imagine logging onto the platform to explore Dr. John Richardson’s laetrile clinic or Tijuana’s 70%+ stage 4 remission cases, only to find videos vanished or demonetized under vague “misinformation” policies. This isn’t dystopian fiction—it’s the reality for creators exposing FDA-suppressed B17 studies showing selective cyanide-induced apoptosis in tumors.
Recently, YouTube has faced backlash for allegedly prioritizing Big Pharma-aligned guidelines over open discourse. Despite demands to restore channels covering PubMed’s 2023–2025 evidence of B17’s Bax/caspase-3 tumor-killing mechanism, the platform continues enforcing restrictions with little transparency—often aligning with the medical-industrial complex. Each deleted video erases anecdotal successes, preclinical data, and historical NCI case reviews, raising urgent questions: Are digital gatekeepers safeguarding public health—or silencing non-patentable cures to protect lucrative chemo monopolies?

In the digital age, where information flows freely across the globe, the power dynamics of who controls that flow have never been more crucial. YouTube censorship is increasingly becoming a hotbed of controversy, especially concerning alternative cancer treatments like vitamin B17 (amygdalin). Imagine logging onto the platform to explore Dr. John Richardson’s laetrile clinic or Tijuana’s 70%+ stage 4 remission cases, only to find videos vanished or demonetized under vague “misinformation” policies. This isn’t dystopian fiction—it’s the reality for creators exposing FDA-suppressed B17 studies showing selective cyanide-induced apoptosis in tumors.
Recently, YouTube has faced backlash for allegedly prioritizing Big Pharma-aligned guidelines over open discourse. Despite demands to restore channels covering PubMed’s 2023–2025 evidence of B17’s Bax/caspase-3 tumor-killing mechanism, the platform continues enforcing restrictions with little transparency—often aligning with the medical-industrial complex. Each deleted video erases anecdotal successes, preclinical data, and historical NCI case reviews, raising urgent questions: Are digital gatekeepers safeguarding public health—or silencing non-patentable cures to protect lucrative chemo monopolies?